Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials

被引：0
|
作者：
Sandborn, W. J. [1 ]
Panes, J. [2 ]
D'Haens, G. R. [3 ]
Sands, B. E. [4 ]
Su, C. [5 ]
Moscariello, M. [5 ]
Jones, T. V. [5 ]
Pedersen, R. D. [5 ]
Friedman, G. S. [5 ]
Lawendy, N. [5 ]
Chan, G. [5 ]
机构：
[1] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA
[2] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[3] Acad Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
[4] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
[5] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP023
引用
收藏
页码：S45 / S46
页数：3
相关论文
共 50 条
  • [41] Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
    Taxonera, C.
    Ha, C.
    Fortes, M. del Pilar
    Gardiner, S.
    Mundayat, R.
    Ghosh, S.
    Connor, S. J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 678 - 679
  • [42] Characterization of Hospitalized Patients With Ulcerative Colitis Treated With Tofacitinib in the OCTAVE Clinical Program for up to 7.8 Years
    Taxonera, Carlos
    Ha, Christina
    del Pilar Fortes, Maria
    Gardiner, Sean
    Mundayat, Rajiv
    Ghosh, Subrata
    Connor, Susan J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S914 - S915
  • [43] Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the Ulcerative Colitis Clinical Program as of May 2019
    Lichtenstein, Gary R.
    Ciorba, Matthew A.
    Rogler, Gerhard
    Sharara, Ala
    Sunna, Nancy
    Mundayat, Rajiv
    Judd, Donna T.
    Lawendy, Nervin
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S464 - S464
  • [44] TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE OCTAVE CLINICAL PROGRAM
    Winthrop, Kevin L.
    Loftus, Edward V.
    Baumgart, Daniel C.
    Reinisch, Walter
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Lawendy, Nervin
    Chan, Gary
    Pedersen, Ronald D.
    Friedman, Gary S.
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S388 - S388
  • [45] Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
    Lichtenstein, Gary R.
    Bressler, Brian
    Francisconi, Carlos
    Vermeire, Severine
    Lawendy, Nervin
    Salese, Leonardo
    Sawyerr, Gosford
    Shi, Hongjiong
    Su, Chinyu
    Judd, Donna T.
    Jones, Thomas
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (01) : 27 - 41
  • [46] Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme
    Winthrop, K. L.
    Loftus, E. V., Jr.
    Baumgart, D. C.
    Reinisch, W.
    Thorpe, A. J.
    Nduaka, C. I.
    Lawendy, N.
    Chan, G.
    Pedersen, R. D.
    Friedman, G. S.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S351 - S352
  • [47] TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF MALIGNANCY RATES FROM THE OCTAVE CLINICAL PROGRAM
    Lichtenstein, Gary R.
    Ciorba, Matthew A.
    Rogler, Gerhard
    Quirk, Daniel
    Nduaka, Chudy I.
    Pedersen, Ronald D.
    Lawendy, Nervin
    Chan, Gary
    Su, Chinyu
    Panes, Julian
    GASTROENTEROLOGY, 2018, 154 (06) : S385 - S386
  • [48] Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
    Lichtenstein, G. R.
    Ciorba, M. A.
    Rogler, G.
    Quirk, D.
    Nduaka, C. I.
    Pedersen, R. D.
    Lawendy, N.
    Chan, G.
    Su, C.
    Panes, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S48 - S49
  • [49] Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
    Curtis, Jeffrey R.
    Regueiro, Miguel
    Yun, Huifeng
    Su, Chinyu
    DiBonaventura, Marco
    Lawendy, Nervin
    Nduaka, Chudy, I
    Koram, Nana
    Cappelleri, Joseph C.
    Chan, Gary
    Modesto, Irene
    Lichtenstein, Gary R.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (09) : 1394 - 1408
  • [50] Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials
    Langley, Richard G. B.
    Cohen, Arnon D.
    Foley, Peter
    Griffiths, Christopher E. M.
    Lebwohls, Mark
    Leonardi, Craig
    Winthrop, Kevin
    Proulx, James
    Rottinghaus, Scott T.
    Wolk, Robert
    Thompson, John R.
    Tatulych, Svitlana
    Mallbris, Lotus
    Swanson, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
12345